Trump approves new drug pricing deals

President Donald Trump announced the signing of new agreements with nine pharmaceutical companies to voluntarily lower drug prices, aiming to link U.S. prices to those abroad. These agreements include discounts on medications for chronic and rare diseases, such as hemophilia, liver conditions, and cancer, covering approximately 90% of the American pharmaceutical market. This move comes as part of efforts to reduce healthcare costs ahead of the midterm elections, with continued negotiations with other companies to achieve the goal of lowering prices and establishing greater balance in the drug market.